- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06233474
Een gerandomiseerde, dubbelblinde, placebogecontroleerde fase 1/2a-studie van intra-articulaire Allocetra bij artrose in de knie
This is a double blind, randomized,multi-center study to evaluate the safety and efficacy of intra-articular administration of Allocetra compared to placebo in patients with symptomatic knee osteoarthritis.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Knee osteoarthritis is a degenerative disease driven by physical breakdown of the joint cartilage, together with a chronic inflammation within the knee space. Over time, many patients will develop worsening pain in the joint and functional impairment, which may ultimately require knee replacement.
Allocetra is an immunomodulatory cell-based therapy consisting of allogeneic peripheral blood mononuclear cells that have been modified to be engulfed by macrophages and reprogram them into their homeostatic state.
This Phase 1/2a study is comprised of an open-label safety run-in stage to characterize safety and tolerability of repeated injections of Allocetra to a target knee , followed by a double-blind randomized stage to evaluate the safety and efficacy of Allocetra repeated injections to the target knee compared to placebo, in moderate to severe knee osteoarthritis patients. Patients in both stages will be followed for up to a year following last treatment. the last treatment.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
- Fase 1
Contacten en locaties
Studie Locaties
-
-
-
Gandrup, Denemarken, 9362
- Sanos Clinic Nordjylland
-
Herlev, Denemarken, 2730
- Sanos Clinic Herlev
-
Vejle, Denemarken, 7100
- Sanos Clinic Syddanmark
-
-
-
-
-
Ashkelon, Israël, 7830604
- Barzilai Medical Center
-
Haifa, Israël, 7651211
- Rambam Medical Center
-
Petah Tikva, Israël, 4937211
- Hasharon Medical Center
-
Ramat Gan, Israël, 5266202
- Sheba Medical Center
-
Rehovot, Israël, 7661041
- Kaplan Medical Center
-
Tel Aviv, Israël, 6423906
- Ichilov - Tel Aviv Sourasky Medical Center
-
-
-
-
-
Chisinau, Moldavië, 2025
- IMSP Institutul de Cardiologie
-
Chisinau, Moldavië, 2025
- Spitalul Clininc Republican "T. Mosneaga"
-
Chisinau, Moldavië, 2068
- IMSP Sptalul Clinic Municipal "Sfanta Treime"
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age 45 - 80 years.
- Chronic osteoarthritis of index knee with knee-related joint pain
- Radiographic evidence of knee osteoarthritis of K-L Grade 2 or 3 in the index knee.
- Knee pain assessed daily over a period of 7 days during the screening period and following wash-out of pain medications
- Patients with chronic knee pain for at least 3 months who have failed to respond adequately to conventional therapy.
- Willing to abstain from other intra-articular treatments and adhere to the protocol restrictions for concomitant medications and therapies during the study.
- Women of childbearing potential and all men must agree to use 2 methods of an adequate contraception prior to study entry and for the duration of study participation through 4 weeks following IP administration.
Exclusion Criteria:
- Wheelchair bound.
- Immunosuppressive therapy
- Any known current or prior tumor of the index knee.
- Any known history or current intra-articular or osseous infection of the index knee.
- Any evidence of clinically significant active infection
- Any known history of inflammatory arthropathy or crystal-deposition arthropathy
- Any known severe systemic cartilage and/or bone disorder, such as, but not limited to, chondrodysplasia, osteogenesis imperfecta.
- Body Mass Index (BMI) >40.
- Any major surgical cartilage treatment within 6 months
- Any ligamentous repair or malalignment correction in the index knee within 6 months
- Major injury to the index knee, such as torn ligament or severe sprain within 6 months
- Clinically relevant knee instability of the index knee
- Severe hip osteoarthritis ipsilateral to the index knee.
- Clinically significant widespread pain syndromes, e.g., fibromyalgia, long COVID syndrome.
- Known coagulopathy, or use of anticoagulation medication or antiaggregant medication;.
- certain tumors, severe cardiac, respiratory or hematologic diseases as defined in the protocol
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Ander: Safety run-in phase - Allocetra increasing dose
An open-label dose escalation phase to characterize the safety and tolerability of Allocetra injections to the knee in different doses and select the Allocetra dose and regimen for the randomized phase. |
Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, induced to an apoptotic stable state |
|
Placebo-vergelijker: Randomization phase - Placebo.
Three intra-articular injections of placebo into the index knee. |
The control used in this study will be placebo. Placebo solution containing all excipients except for the Allocetra cells. |
|
Experimenteel: Randomization phase - Allocetra
Three intra-articular injections of Allocetra at a selected dose, into the index knee. |
Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, induced to an apoptotic stable state |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Treatment-emergent adverse events and Serious adverse events following Allocetra-OTS injection
Tijdsspanne: 7 months following Day 0
|
Number and severity of adverse events (AEs), serious adverse events (SAEs) and treatment disruptions/ discontinuations throughout the study from Day 0 and up to 6 months following the last injection |
7 months following Day 0
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Weekly average of knee pain.
Tijdsspanne: 4 months and 7 months following Day 0.
|
Evaluation of change from baseline in weekly average of knee pain as measured using NRS (Numeric Rating Scale ) assessed at 3 months and 6 months from last study treatment. Scores range from 0-10 points, with higher scores indicating greater pain intensity |
4 months and 7 months following Day 0.
|
|
Change from baseline in WOMAC total score.
Tijdsspanne: 4 months, 7 months and 13 months following Day 0.
|
Change from baseline in Western Ontario and McMaster Universities Arthritis Index (WOMAC) total score at 3 months, 6 months, and 12 months from last study treatment administration. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations. |
4 months, 7 months and 13 months following Day 0.
|
|
Change in quality of life- Euro Quality of Life-5-dimension (EQ-5D) questionnaire
Tijdsspanne: 4 months, 7 months and 13 months following Day 0.
|
Change from baseline in QoL as measured by Euro Quality of Life-5-dimension (EQ-5D) questionnaire at 6 months and at 12 months from last study treatment administration. |
4 months, 7 months and 13 months following Day 0.
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Studie directeur: Lital Weinfeld-Bergman, Senior Director of Clinical Operations
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- ENX-CL-05-001
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .